Prosecution Insights
Last updated: July 17, 2026
Application No. 19/286,707

EpigenAU/11: A NATURAL MATRIX WITH THERAPEUTIC ACTIVITY THROUGH A PHYSIOLOGICAL NETWORK MECHANISM OF ACTION (NOT PHARMACOLOGICAL) FOR RESTORING HOMEOSTASIS IN TISSUES INFILTRATED BY CANCER CELLS

Non-Final OA §112
Filed
Jul 31, 2025
Priority
Jun 17, 2024 — divisional of 18/744,862 +4 more
Examiner
MI, QIUWEN
Art Unit
1655
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Bios-Therapy Physiological Systems For Health S P A
OA Round
3 (Non-Final)
68%
Grant Probability
Favorable
3-4
OA Rounds
1y 7m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 68% — above average
68%
Career Allowance Rate
1082 granted / 1585 resolved
+8.3% vs TC avg
Strong +50% interview lift
Without
With
+49.7%
Interview Lift
resolved cases with interview
Typical timeline
2y 6m
Avg Prosecution
41 currently pending
Career history
1618
Total Applications
across all art units

Statute-Specific Performance

§101
3.9%
-36.1% vs TC avg
§103
72.7%
+32.7% vs TC avg
§102
15.4%
-24.6% vs TC avg
§112
7.3%
-32.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1585 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . CONTINUED EXAMINATIONS A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 3/23/26 has been entered. DETAILED ACTION Applicant’s amendment in the reply filed on 3/23/26 is acknowledged, with newly added claim 32. Claims 28-32 are pending. Claims 28-32 are examined on the merits. Any rejection that is not reiterated is hereby withdrawn. Claim Rejections –35 USC § 112, 2nd The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 28-31 remain rejected, and claim 32 is newly rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. This rejection is maintained for reasons of record set forth in the Office Action mailed out on 1/22/26, repeated below, slightly altered to take into consideration Applicant’s amendment filed on 3/23/26. Applicants’ arguments filed have been fully considered but they are not deemed to be persuasive. Claim 28 recites “A method for determining the presence of native natural intelligence in in one or more batches of an anti-cancer product…” at lines 1-2; and “wherein native natural intelligence is the ability to self-organize and adapt to environment stimuli without artificial intervention” at lines two lines. The recitation is very confusing, it is not clear what Applicant means by “wherein native natural intelligence is the ability to self-organize and adapt to environment stimuli without artificial intervention”. What “self” refers to here? The claimed product or the subject who is being administered with the claimed product? Does “ability to self-organize” mean the claimed product could dust itself on a daily basis? Does “without artificial intervention” mean the product could automatically feed the subject in need thereof? Applicant is recommended to recite “A method for determining biological and physical-chemical properties of a product…” instead of “determining the presence of native natural intelligence”. Therefore, the metes and bounds of claims are rendered vague and indefinite. The lack of clarity renders the claims very confusing and ambiguous since the resulting claims do not clearly set forth the metes and bounds of the patent protection desired. All other cited claims depend directly or indirectly from rejected claims and are, therefore, also, rejected under U.S.C. 112, second paragraph for the reasons set forth above. Applicant's amendments have been fully considered but they are not persuasive, and therefore the rejections in the record are maintained. Conclusion No claim is allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to QIUWEN MI whose telephone number is (571)272-5984. The examiner can normally be reached on Monday-Friday 8:30 am to 5:00 pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Anand Desai can be reached on 571-272-0947. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /Qiuwen Mi/ Primary Examiner, Art Unit 1655
Read full office action

Prosecution Timeline

Jul 31, 2025
Application Filed
Oct 28, 2025
Non-Final Rejection mailed — §112
Dec 30, 2025
Response Filed
Jan 22, 2026
Final Rejection mailed — §112
Mar 23, 2026
Request for Continued Examination
Mar 25, 2026
Response after Non-Final Action
Apr 22, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12678514
ALGAE-BASED MICROROBOT FOR DRUG DELIVERY
2y 3m to grant Granted Jul 14, 2026
Patent 12673019
SKIN CARE COMPOSITION
2y 1m to grant Granted Jul 07, 2026
Patent 12661313
COSMETIC COMPOSITION
1y 11m to grant Granted Jun 23, 2026
Patent 12653774
TOPICAL COMPOSITIONS AND METHODS FOR USING SAME
3y 1m to grant Granted Jun 16, 2026
Patent 12653772
USE OF A ROSEBUSH EXTRACT AS DEPIGMENTING ACTIVE AGENT
3y 0m to grant Granted Jun 16, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
68%
Grant Probability
99%
With Interview (+49.7%)
2y 6m (~1y 7m remaining)
Median Time to Grant
High
PTA Risk
Based on 1585 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month